Kelun-Biotech to Present Final Os Analysis Mar 18

The Story

Kelun-Biotech announced it will present the final OS analysis of sacituzumab tirumotecan (sac-TMT) from the pivotal OptiTROP-Lung03 study at the 2026 European Lung Cancer Congress. The ELCC runs in Copenhagen from Mar 25 to Mar 28, 2026, and the presentation is the primary upcoming clinical milestone cited by the company.

Why It Matters For Your Portfolio

• The OptiTROP-Lung03 study is described as pivotal, so the final OS analysis could be the last major clinical readout before potential regulatory or partnering actions, which may affect valuation and deal interest.
• The presentation timing, Mar 25-28, 2026, gives a clear, date-bound catalyst that can increase news flow and volatility around the stock and peer biotech names during that window.
• Sacituzumab tirumotecan (Sac-TMT) is the therapy under review in OptiTROP-Lung03, so the OS outcome directly ties to Kelun-Biotech's clinical program progress and future development priorities.

The Trade

This is primarily relevant for clinical-stage biotech investors and short-term traders who monitor event-driven volatility. Watch for the ELCC presentation and any immediate press release or data tables that follow, since the company has flagged the final OS analysis as the key upcoming data point. Be prepared for increased headlines around Mar 25-28, 2026 and for follow-up commentary from investigators and regulators.